Xtandiwhich is also approved for four other types of prostate canceris the first androgen receptor signaling inhibitor authorized to treat nmCSPC with biochemical recurrence at high risk for metastasis, according to the companies announcement

Ingredients Synthetic Wax, Dimethicone, Silica, Butylene Glycol Dicaprylate/Dicaprate, Octocrylene, Ethylhexyl Methoxycinnamate, Vinyl Dimethicone/Methicone Silsesquioxane Crosspolymer, Butyloctyl Salicylate, Cetyl Ethylhexanoate, Dicaprylyl Carbonate, Ethylhexyl Salicylate, Diethylamino Hydroxybenzoyl Hexyl Benzoate, Bis-Ethylhexyl Methoxyphenyl Triazine, Tocopheryl Acetate, Tocopherol, Water, Butylene Glycol, 1,2-Hexanediol, Poterium Officinale Root Extract, Veronica Officinalis Extract, Microcrystalline Wax, BHT, Caprylyl Glycol, Bisabolol, Polyglyceryl-4 Diisostearate/Polyhydroxy-stearate/Sebacate, Fragrance, Glutathione, Sodium Hyaluronate, Methylpropanediol, Paeonia Albiflora Flower Extract, Hippophae Rhamnoides Fruit Extract, Sodium DNA Content 11 g / 0.38 oz For Topical and Cosmetic Use Only

doi:10.1089/acm.2011.0503, PMID: 22757691 Ding W, Liu Y (2011) Genistein attenuates genioglossus muscle fatigue under chronic intermittent hypoxia by down-regulation of oxidative stress level and up-regulation of antioxidant enzyme activity through ERK1/2 signaling pathway
However, further research in humans is still needed to confirm its effectiveness.
Comparative genomic mapping implicates LRRK2 for intellectual disability and autism at 12q12, and HDHD1, as well as PNPLA4, for X-linked intellectual disability at Xp22.31